Formycon AG (ETR:FYB)
25.35
+0.35 (1.40%)
Aug 12, 2025, 5:35 PM CET
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€278,696
Profits / Employee
€502,688
Market Cap
441.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 250 | 12 | 5.04% |
Dec 31, 2023 | 238 | 33 | 16.10% |
Dec 31, 2022 | 205 | 34 | 19.88% |
Dec 31, 2021 | 171 | 40 | 30.53% |
Dec 31, 2020 | 131 | 18 | 15.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 59,020 |
Bayer Aktiengesellschaft | 91,864 |
Fresenius SE & Co. KGaA | 176,486 |
Fresenius Medical Care AG | 111,513 |
Sartorius Aktiengesellschaft | 13,528 |
Fielmann Group AG | 24,363 |
Carl Zeiss Meditec AG | 5,730 |
Formycon AG News
- 13 days ago - EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025 - Wallstreet:Online
- 27 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon successfully completes patient enrollment for the clinical development of its Keytruda biosimilar candidate FYB206 - Wallstreet:Online
- 6 weeks ago - EQS-News: Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta (ranibizumab) across Sub-Saharan Africa - Wallstreet:Online
- 6 weeks ago - EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond - Wallstreet:Online
- 6 weeks ago - EQS-News: Teva becomes secondary commercialization partner for Formycon's Stelara biosimilar FYB202 (ustekinumab) under the brand name Fymskina in Germany - Wallstreet:Online
- 6 weeks ago - EQS-News: U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/AHZANTIVE (aflibercept-mrbb) in the United States and Canada - Wallstreet:Online
- 6 weeks ago - EQS-News: Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period - Wallstreet:Online